Dimitrios Colevas
Stanford University
6 Papers
14 Citations
Dimitrios Colevas is an academic researcher from Stanford University. The author has contributed to research in topics: Cetuximab & Cancer. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients
Hongbin Cao,Alice Banh,Shirley Kwok,Xiaoli Shi,Simon Wu,Trevor E. Krakow,Brian Khong,Brindha Bavan,Rajeev Bala,Benjamin A. Pinsky,Dimitrios Colevas,Nader Pourmand,Albert C. Koong,Christina S. Kong,Quynh-Thu Le +14 more
TL;DR: Xenograft studies indicated that plasma HPV DNA is released from HPV-positive tumors and might be a valuable tool for identifying relapse.
129
Advances in Nanotechnology and Microfluidics for Human Papillomavirus Diagnostics
Savas Tasoglu,H. Cumhur Tekin,Fatih Inci,Stephanie Knowlton,ShuQi Wang,ShuQi Wang,Feng Wang-Johanning,Gary L. Johanning,Dimitrios Colevas,Utkan Demirci +9 more
- 24 Mar 2015
TL;DR: There is high clinical utility of HPV diagnostics even with binary positive/negative indication of the presence of HPV in patient samples, and recent advances in nanotechnology and microfluidics that potentially enable new approaches for HPV diagnosis are highlighted.
40
Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data
Roger B. Cohen,G. Lefebvre,Marshall R. Posner,Jessica Bauman,Sébastien Salas,Caroline Even,Esma Saada-Bouzid,T. Seiwert,Dimitrios Colevas,F. Calmels,R. Zerbib,P. Andre,A. Boyer-Chammard,J. Fayette +13 more
TL;DR: In a cohort of 40 patients of heavily pretreated SCCHN patients, monalizumab and cetuximab combination demonstrated high response rate, good duration of response, and promising PFS and OS as well as good safety profile.
20
Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy
Roger B. Cohen,Jérôme Fayette,Marshall R. Posner,G. Lefebvre,Jessica Bauman,Sébastien Salas,Caroline Even,Tanguy Y. Seiwert,Dimitrios Colevas,Antonio Jimeno,Esma Saada,Barbara Burtness,Pascale Andre,Carine Paturel,Cécile Bonnafous,Anne-Marie Soulié,Anne Tirouvanziam-Martin,Robert Zerbib,Agnès Boyer-Chammard +18 more
TL;DR: Preliminary data suggest promising antitumor activity of the combination of monalizumab and cetuximab compared to historical data with single agent cetUXimab, with acceptable safety, will need to be confirmed on larger sample size with longer follow up.
14
Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck.
Antonio Jimeno,Thomas J. Galloway,Lori J. Wirth,Jill Gilbert,Nabil F. Saba,Julie E. Bauman,Dimitrios Colevas,Ranee Mehra,David Raben,Chengjung Lai,Robert Laliberte,Maurizio Voi,Barbara Burtness +12 more
TL;DR: The results of this study showed that CUDC-101 can be combined with chemoradiation at a dose of 275 mg/m2 with ARF being the most prominent DLT and preliminary long-term efficacy results are encouraging.
1